Patient Guide: A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 8 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT07459543
Status: NOT_YET_RECRUITING
Condition: Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma
Phase: PHASE4

Find a Study Location Near You

This study is available at 8 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Navi Mumbai, Maharashtra
  • Pune, Maharashtra
  • Bhubaneswar, Odisha
  • • And 5 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily